PANITUMUMAB

Panitumumab Adverse Events Reported to the FDA Over Time

How are Panitumumab adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Panitumumab, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Panitumumab is flagged as the suspect drug causing the adverse event.

Most Common Panitumumab Adverse Events Reported to the FDA

What are the most common Panitumumab adverse events reported to the FDA?

Diarrhoea	605 (4.12%)
Dermatitis Acneiform	595 (4.05%)
Dehydration	428 (2.91%)
Stomatitis	420 (2.86%)
Colorectal Cancer	372 (2.53%)
Interstitial Lung Disease	310 (2.11%)
Febrile Neutropenia	277 (1.88%)
Hypomagnesaemia	276 (1.88%)
Paronychia	249 (1.69%)
Decreased Appetite	232 (1.58%)
Pyrexia	229 (1.56%)
	Show More
Vomiting	215 (1.46%)
Dry Skin	203 (1.38%)
Neutropenia	199 (1.35%)
Nausea	196 (1.33%)
Rash	193 (1.31%)
Pneumonia	169 (1.15%)
Anaemia	164 (1.12%)
Hypocalcaemia	159 (1.08%)
Hypokalaemia	152 (1.03%)
Fatigue	139 (.95%)
Pulmonary Embolism	139 (.95%)
White Blood Cell Count Decreased	127 (.86%)
Neutrophil Count Decreased	120 (.82%)
Mucosal Inflammation	116 (.79%)
Dyspnoea	115 (.78%)
Malaise	114 (.78%)
Asthenia	113 (.77%)
Death	109 (.74%)
Sepsis	108 (.73%)
Hypotension	101 (.69%)
Deep Vein Thrombosis	96 (.65%)
Infection	89 (.61%)
Thrombocytopenia	88 (.6%)
Pruritus	86 (.59%)
General Physical Health Deteriorati...	81 (.55%)
Dermatitis	78 (.53%)
Renal Failure Acute	78 (.53%)
Acne	77 (.52%)
Pancytopenia	73 (.5%)
Hyponatraemia	69 (.47%)
Platelet Count Decreased	69 (.47%)
Neutropenic Sepsis	68 (.46%)
Haemoglobin Decreased	66 (.45%)
Abdominal Pain	62 (.42%)
Anorexia	61 (.41%)
Intestinal Obstruction	60 (.41%)
Urinary Tract Infection	60 (.41%)
Atrial Fibrillation	59 (.4%)
Renal Failure	58 (.39%)
Dysphagia	57 (.39%)
Infusion Related Reaction	53 (.36%)
Weight Decreased	53 (.36%)
Dizziness	52 (.35%)
Ileus	51 (.35%)
Malignant Neoplasm Progression	49 (.33%)
Hepatic Function Abnormal	48 (.33%)
Blood Creatinine Increased	47 (.32%)
Disease Progression	47 (.32%)
Pleural Effusion	46 (.31%)
Thrombosis	46 (.31%)
Neuropathy Peripheral	45 (.31%)
Leukopenia	44 (.3%)
Blood Magnesium Decreased	43 (.29%)
Gastrointestinal Haemorrhage	43 (.29%)
Cerebral Infarction	42 (.29%)
Respiratory Failure	42 (.29%)
Chills	40 (.27%)
Oedema Peripheral	40 (.27%)
Back Pain	39 (.27%)
Hyperkalaemia	39 (.27%)
Hypoalbuminaemia	39 (.27%)
Electrolyte Imbalance	38 (.26%)
Syncope	38 (.26%)
Cellulitis	37 (.25%)
Convulsion	37 (.25%)
Blood Calcium Decreased	36 (.24%)
Folliculitis	36 (.24%)
Hypersensitivity	36 (.24%)
Confusional State	35 (.24%)
Multi-organ Failure	34 (.23%)
Blood Sodium Decreased	33 (.22%)
Hypoxia	33 (.22%)
Skin Fissures	33 (.22%)
Small Intestinal Obstruction	32 (.22%)
Venous Thrombosis	32 (.22%)
Chest Pain	31 (.21%)
Glossitis	31 (.21%)
Haematocrit Decreased	31 (.21%)
Erythema	30 (.2%)
Disseminated Intravascular Coagulat...	29 (.2%)
Pain	29 (.2%)
Ascites	28 (.19%)
Colitis	28 (.19%)
Intestinal Perforation	28 (.19%)
Septic Shock	28 (.19%)
Blood Potassium Decreased	27 (.18%)
Dysgeusia	27 (.18%)
Lethargy	27 (.18%)
Pneumonitis	27 (.18%)
Alanine Aminotransferase Increased	26 (.18%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Panitumumab, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Panitumumab is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Panitumumab

What are the most common Panitumumab adverse events reported to the FDA?

Infections - Pathogen Unspecified	1151 (7.83%)
Epidermal And Dermal Conditions	779 (5.3%)
Electrolyte And Fluid Balance Condi...	748 (5.09%)
Skin Appendage Conditions	726 (4.94%)
Gastrointestinal Motility And Defec...	639 (4.35%)
Gastrointestinal Signs	565 (3.84%)
White Blood Cell	555 (3.78%)
Hematology Investigations	512 (3.48%)
Oral Soft Tissue Conditions	506 (3.44%)
Bone, Calcium, Magnesium And Phosph...	472 (3.21%)
Lower Respiratory Tract Disorders	438 (2.98%)
	Show More
Gastrointestinal Neoplasms Malignan...	426 (2.9%)
Appetite And General Nutritional	338 (2.3%)
Respiratory	299 (2.03%)
Anemias Nonhemolytic And Marrow Dep...	280 (1.9%)
Neurological	262 (1.78%)
Body Temperature Conditions	241 (1.64%)
Embolism And Thrombosis	230 (1.56%)
Bacterial Infectious	222 (1.51%)
Renal Disorders	205 (1.39%)
Water, Electrolyte And Mineral	202 (1.37%)
Gastrointestinal Stenosis And Obstr...	173 (1.18%)
Cardiac Arrhythmias	166 (1.13%)
Pulmonary Vascular	158 (1.07%)
Decreased And Nonspecific Blood Pre...	140 (.95%)
Hepatic And Hepatobiliary	131 (.89%)
Gastrointestinal Hemorrhages	127 (.86%)
Gastrointestinal Ulceration And Per...	126 (.86%)
Gastrointestinal Inflammatory Condi...	124 (.84%)
Fatal Outcomes	116 (.79%)
Central Nervous System Vascular	109 (.74%)
Platelet	92 (.63%)
Hepatobiliary	84 (.57%)
Administration Site Reactions	80 (.54%)
Miscellaneous And Site Unspecified ...	80 (.54%)
Renal And Urinary Tract Investigati...	79 (.54%)
Physical Examination Topics	71 (.48%)
Coronary Artery	68 (.46%)
Pleural	67 (.46%)
Ocular Infections, Irritations And ...	65 (.44%)
Injuries	64 (.44%)
Tongue Conditions	60 (.41%)
Peripheral Neuropathies	59 (.4%)
Musculoskeletal And Connective Tiss...	55 (.37%)
Allergic Conditions	53 (.36%)
Metastases	53 (.36%)
Urinary Tract Signs	53 (.36%)
Deliria	51 (.35%)
Enzyme	48 (.33%)
Peritoneal And Retroperitoneal Cond...	48 (.33%)
Protein And Amino Acid Metabolism	48 (.33%)
Seizures	48 (.33%)
Fungal Infectious	43 (.29%)
Procedural And Device Related Injur...	43 (.29%)
Muscle	42 (.29%)
Cardiac And Vascular Investigations	40 (.27%)
Coagulopathies And Bleeding Diathes...	39 (.27%)
Heart Failures	39 (.27%)
Viral Infectious	38 (.26%)
Upper Respiratory Tract Disorders	37 (.25%)
Bone And Joint Injuries	35 (.24%)
Neoplasm Related Morbidities	35 (.24%)
Movement Disorders	34 (.23%)
Microbiology And Serology	33 (.22%)
Protein And Chemistry Analyses	31 (.21%)
Skin And Subcutaneous Tissue	31 (.21%)
Glucose Metabolism Disorders	29 (.2%)
Metabolic, Nutritional And Blood Ga...	29 (.2%)
Angiedema And Urticaria	25 (.17%)
Bronchial Disorders	25 (.17%)
Vascular Hypertensive	25 (.17%)
Encephalopathies	24 (.16%)
Bile Duct	23 (.16%)
Acid-base	22 (.15%)
Psychiatric	19 (.13%)
Congenital And Hereditary	18 (.12%)
Gastrointestinal Vascular Condition...	18 (.12%)
Myocardial	18 (.12%)
Tissue	18 (.12%)
Injuries By Physical Agents	17 (.12%)
Vascular	17 (.12%)
Chemical Injury And Poisoning	16 (.11%)
Headaches	15 (.1%)
Cardiac Disorder Signs	14 (.1%)
Gallbladder	14 (.1%)
Medication Errors	14 (.1%)
Arteriosclerosis, Stenosis, Vascula...	13 (.09%)
Bladder And Bladder Neck Disorders	12 (.08%)
Lifestyle Issues	12 (.08%)
Skin Vascular Abnormalities	11 (.07%)
Vascular Hemorrhagic	11 (.07%)
Anterior Eye Structural Change, Dep...	10 (.07%)
Anxiety Disorders	10 (.07%)
Joint	10 (.07%)
Therapeutic And Nontherapeutic Effe...	10 (.07%)
Bone Disorders	9 (.06%)
Cardiac Valve	9 (.06%)
Diverticular	9 (.06%)
Inner Ear And Viiith Cranial Nerve	9 (.06%)
Aneurysms And Artery Dissections	8 (.05%)
Reproductive Tract	8 (.05%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Panitumumab, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Panitumumab is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.